Telomir Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $2.4M | $2.2M | $1.6M | $833,206 | — |
| Operating expenses | $10.5M | $12.2M | $3.9M | $854,147 | — |
| Interest expense | — | $4.3M | $1.6M | — | — |
| Net income | -$10.4M | -$16.5M | -$13.1M | -$854,147 | — |
| Balance Sheet | |||||
| Current assets | $7.3M | $1.3M | $435,225 | $48,730 | — |
| Total assets | $7.3M | $1.3M | $4.8M | $48,730 | — |
| Current liabilities | $1.4M | $680,968 | $1.3M | $986,008 | — |
| Total liabilities | $1.4M | $680,968 | $1.3M | $986,008 | — |
| Total debt | — | $100,000 | $500,000 | $600,000 | — |
| Stockholders' equity | $5.9M | $643,037 | $3.4M | -$937,278 | -$138,131 |
| Cash Flow Statement | |||||
| Cash from operations | -$3.7M | -$5.1M | -$3.9M | -$468,661 | — |
| Stock-based compensation | $5.3M | $6.9M | — | — | — |
Shares outstanding 68.8M · Free float 81.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.